3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Colorectal Neoplasms
30
Carcinoma, Hepatocellular
13
Rectal Neoplasms
5
Sarcoma, Ewing
4
Osteosarcoma
4
Gastrointestinal Stromal Tumors
4
Colonic Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasm Metastasis
3
Glioblastoma
3
Sarcoma
2
Neoplasms
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Esophageal Neoplasms
2
Chondrosarcoma
2
Bone Neoplasms
2
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Spinocerebellar Degenerations
1
Solid Malignant Tumors
1
Small Cell Lung Carcinoma
1
Recurrence
1
Piebaldism
1
Patient Compliance
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Interventions
Carboplatin
6
pembrolizumab
3
Paclitaxel
3
Observation
3
Capecitabine
3
Azacitidine
3
venetoclax
2
pertuzumab
2
olaparib
2
durvalumab
2
Tretinoin
2
Trastuzumab
2
Standard of Care
2
Oxaliplatin
2
Irinotecan
2
Immunotherapy
2
Chemoradiotherapy
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
toripalimab
1
tislelizumab
1
tegafur-gimeracil-oteracil
1
taxane
1
talazoparib
1
tagraxofusp
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
regorafenib
×
1 year
×
Clear all
NCT04055220
2026-02-17
REGOSTA
Centre Leon Berard
Phase NA
Recruiting
168 enrolled